Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Current Investments: 2015-2025

Historic Cash & Current Investments for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $232.6 million.

  • Assembly Biosciences' Cash & Current Investments rose 144.92% to $232.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $510.6 million, marking a year-over-year increase of 14.14%. This contributed to the annual value of $112.1 million for FY2024, which is 13.95% down from last year.
  • Assembly Biosciences' Cash & Current Investments amounted to $232.6 million in Q3 2025, which was up 210.16% from $75.0 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Cash & Current Investments ranged from a high of $232.6 million in Q3 2025 and a low of $46.2 million during Q3 2023.
  • Its 3-year average for Cash & Current Investments is $103.4 million, with a median of $95.0 million in 2024.
  • Per our database at Business Quant, Assembly Biosciences' Cash & Current Investments tumbled by 57.47% in 2023 and then skyrocketed by 144.92% in 2025.
  • Over the past 5 years, Assembly Biosciences' Cash & Current Investments (Quarterly) stood at $146.6 million in 2021, then plummeted by 37.52% to $91.6 million in 2022, then skyrocketed by 42.18% to $130.2 million in 2023, then fell by 13.95% to $112.1 million in 2024, then spiked by 144.92% to $232.6 million in 2025.
  • Its Cash & Current Investments was $232.6 million in Q3 2025, compared to $75.0 million in Q2 2025 and $91.0 million in Q1 2025.